VRTX vs GILD
VRTX and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $141.70B | $212.04B |
| P/E (TTM) | 32.6 | 25.2 |
| P/B | 7.00 | 16.26 |
| P/S | 11.8x | 7.2x |
| Dividend yield | — | 1.89% |
| Revenue | $12.59B(TTM) | $30.99B(TTM) |
| Revenue growth (YoY) | 8.9% | 2.4% |
| Net income | $4.41B(TTM) | -$3.86B(TTM) |
| Earnings growth (YoY) | 838.1% | 1672.9% |
| EPS, diluted | $17.17(TTM) | $-3.13(TTM) |
| EBIT margin | 34.8% | 34.0% |
| ROE | 19.5% | 65.3% |
| ROIC | 25.0% | 25.7% |
| 1y total return | +33.1% | +47.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: VRTX vs GILD
| Metric | VRTX | GILD |
|---|---|---|
| End value | $65.8K | $29.7K |
| Total return | +557.5% | +197.3% |
| CAGR | +20.0% | +11.1% |
| Volatility | 32.6% | 25.6% |
| Sharpe | 0.60 | 0.38 |
| Sortino | 0.88 | 0.56 |
| Max drawdown | -41.6% | -30.5% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)